Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07206758) titled 'Phase I Study of SHR-2173 Injection in Patients With Primary Immune Thrombocytopenia' on Sept. 26.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd
Condition:
Immune Thrombocytopenia
Intervention:
Drug: SHR-2173 Injection
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: November 2025
Target Sample Size: 10
To know more, visit https://clinicaltrials.gov/study/NCT07206758
Published by HT Digital Content Service...